10.1002/anie.201902174
Angewandte Chemie International Edition
COMMUNICATION
[1] R. G. Powell, D. Weisleder, C. R. Smith, W. K. Rohwedder Tetrahedron
Lett. 1970, 11, 815–818.
[2] (a) N. G. de Loubresse, I. Prokhorova, W. Holtkamp, M. V. Rodnina, G.
Yusupova, M. Yusupov Nature 2014, 513, 517–523, (b) M. Fresno, A.
Jiménez, D. Vázquez Eur. J. Biochem. 1977, 72, 323–330; (c) R. M.
Tujebajeva, D. M. Graifer, G. G. Karpova, N. A. Ajtkhozhina FEBS Lett.
1989, 257, 254–256.
[3] F. Alvandi, V. E. Kwitkowski, C.-W. Ko, M. D. Rothmann, S. Ricci, H. Saber,
D. Ghosh, J. Brown, E. Pfeiler, E. Chikhale, J. Grillo, J. Bullock, R.
Kane, E. Kaminskas, A. T. Farrell, R. Pazdur Oncologist 2014, 19, 94–
99.
[4] (a) J. D. Eckelbarger, J. T. Wilmot, M. T. Epperson, C. S. Thakur, D. Shum,
C. Antczak, L. Tarassishin, H. Djaballah, D. Y. Gin Chem. Eur. J. 2008,
14, 4293–4306; (b) M. Marguerit, G. Little, Y. Wang, L. He, S. Allwein, J.
Reif, J. Rossi, R. Roemmele, R. Bakale Eur. J. Org. Chem. 2015, 36,
8003–8010.
Scheme 5. Kinetic Resolution of Cephalotaxine.
With the undesired (+)-2 in hand, attempts were made to
racemize this material. Previously, Mori
[5] (a) Z. Zhao, Y. Xi, H. Zhao, J. Hou, J. Zhang, Z. Wang Acta Pharmaceutica
Sinica 1980, 15, 46–49; (b) Y.-K. Wang, Y.-L. Li, X.-F. Pan, S.-B. Li,
W.-K. Huang Acta Chimica Sinica 1985, 43, 161–167; (c) S. Hiranuma,
T. Hudlicky Tetrahedron Lett. 1982, 23, 3431–3434; (d) S. Hiranuma, M.
Shibata, T. Hudlicky J. Org. Chem. 1983, 48, 5321–5326; (e) J.-C.
Cheng, J.-H. Zhang, Q.-B. Zhang, J. Yang, L. Huang Yaoxue Xuebao,
1984, 19, 178–183; (f) J.-P. Robin, R. Dhal, G. Dujardin, L. Girodier, L.
Mevellec, S. Poutot Tetrahedron Lett. 1999, 40, 2931–2934; (g) G.-Z.
Ma, P.-F. Li, L. Liu, W.-D. Z. Li, L. Chen Org. Lett. 2017, 19, 2250−2253.
[6] (a) J. Auerbach, S. M. Weinreb J. Am. Chem. Soc. 1972, 94, 7172–7173;
(b) S. M. Weinreb, J. Auerbach J. Am. Chem. Soc. 1975, 97, 2503–
2506.
20
, 22
and Stoltz 21
observed racemization during the methylation of (–)-19 to give
(±)-2 (Scheme 6). They attributed the racemization to formation
of intermediate achiral cyclopentadienone 20. This suggested
racemization of (+)-2 should be possible, and it would allow
recycling of the unwanted cephalotaxinone enantiomer.
Gratifyingly, subjection of (+)-2 to Mori/Stoltz conditions resulted
in racemization, giving (±)-2. This allows simple recycling of the
unwanted enantiomer of cephalotaxinone.23
[7] For review of cephalotaxine syntheses from 1975–2011, see: H. Abdelkafi,
B. Nay Nat. Prod. Rep. 2012, 29, 845–869.
[8] (a) P. Xing, Z.-G. Huang, Y. Jin, B. Jiang A Synthesis 2013, 45, 596–600;
(b) M. G. Gonçalves-Martin, S. Zigmantas, P. Renaud Helv. Chim. Acta
2012, 95, 2502–2514; (c) Q.-W. Zhang, K. Xiang, Y.-Q. Tu, S.-Y. Zhang,
X.-M. Zhang, Y.-M. Zhao, T.-C. Zhang Chem. Asian J. 2012, 7, 894–
898; (d) Z.-W. Zhang, X.-F. Zhang, J. Feng, Y.-H. Yang, C.-C. Wang,
J.-C. Feng, S. Liu J. Org. Chem. 2013, 78, 786−790; (e) K.-J. Xiao, J.-
M. Luo, X.-E. Xia, Y. Wang, P.-Q. Huang Chem. Eur. J. 2013, 19,
13075–13086; (f) S.-H. Huang, X. Tian, X. Mi, Y. Wang, R. Hong
Tetrahedron Lett. 2015, 56, 6656–6658; (g) H. Liu, J. Yu, X. Li, R. Yan,
J.-C. Xiao, R. Hong Org. Lett. 2015, 17, 4444−4447; (h) P. Gouthami, R.
Chegondi, S. Chandrasekhar Org. Lett. 2016, 18, 2044−2046; (i) X.-Y.
Ma, X.-T. An, X.-H. Zhao, J.-Y. Du, Y.-H. Deng, X.-Z. Zhang, C.-A. Fan
Org. Lett. 2017, 19, 2965−2968; (j) Z.-W. Zhang, C.-C. Wang, H. Xue,
Y. Dong, J.-H. Yang, S. Liu, W.-Q. Liu, W.-D. Z. Li Org. Lett. 2018, 20,
1050−1053
Scheme 6. Racemization of Cephalotaxinone.
In summary, we have completed a total synthesis of (–)-
cephalotaxine
transformation involved an oxidative furan opening with
spontaneous transannular Mannnich reaction. Noyori
and
(–)-homoharringtonine.
Our
key
A
reduction converts (±)-cephalotaxinone to (–)-cephalotaxine with
excellent enantioselectivity. The unwanted enantiomer of
cephalotaxinone can be recycled by racemization in high yield.
Overall, our synthesis of (–)-cephalotaxine is 9 steps and occurs
in >5% chemical yield, which compares well with previous
syntheses.
[9] (a) D.-Z. Wang, G.-E. Ma, R.-S. Xu Acta Pharmaceutica Sinica 1992, 27,
178−184. (b) D. Gin, J. Wilmot, H. Djaballah US20110071097A1, Mar
24, 2011; (c) L. Chen, W.-D. Li CN102675327A, Sep 19, 2012; (d) F.
Rong, R. Xu, F. Xie, H. Lai US20140206669A1, Jul 24, 2014; (e) R. Xu,
F. Rong, F. Xie, H. Lai US20140303147A1, Oct 9, 2014.
[10] (a) J. M. Cassady, P.-Z. Cong, R. G. Cooks, R. Roush, C. J. Chang, R. G.
Powell Acta Pharmaceutica Sinica 1988, 23, 351–355; (b) I. Takano, I.
Yasuda, M. Nishijima, Y. Hitotsuyanagi, K. Takeya, H. Itokawa
Tetrahedron Lett. 1996, 37, 7053–7054; (c) H. Morita, M. Arisaka, N.
Yoshida, J. Kobayashi Tetrahedron 2000, 56, 2929–2934; (d) M.
Yoshinaga, H. Morita, T. Dota, J. Kobayashi Tetrahedron 2004, 60,
7861–7868.
Acknowledgements
We acknowledge funding from NSF (CHE-1465287) and Oregon
State University. This paper is dedicated to Professor Larry E.
Overman.
[11] (a) G. Piancatelli, A. Scettri, M. D'Auria Tetrahedron 1980, 36, 661–663;
(b) Y. Kobayashi, H. Katsuno, F. Sato Chem. Lett. 1983, 1771–1774;
(c) L. Lepage, Y. Lepage Synthesis 1983, 12, 1018–1019; (d) K.
Gollnick, A. Griesbeck Tetrahedron 1985, 41, 2057–2068; (e) C.
Dominguez, A. G. Csaky, J. Plumet Tetrahedron Lett. 1990, 31, 7669–
7670; (f) B. J. Adger, C. Barrett, J. Brennan, P. McGuigan, M. A.
McKervey, B. Tarbit J. Chem. Soc., Chem. Commun. 1993, 15, 1220–
1222; (g) J. Wahlen, B. Moens, D. E. De Vos, P. L. Alsters, P. A.
Keywords: homoharringtonine • cephalotaxine • alkaloid •
Mannich • total synthesis
This article is protected by copyright. All rights reserved.